Page 13 - Amy Wolf News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis plans to petition the U.S. Court of Appeals for the Federal Circuit for further review to uphold validity of the Gilenya® (fingolimod) dosing regimen patent

Ad hoc announcement pursuant to Art. 53 LR Basel, June 21, 2021 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit issued a new, negative decision regarding... | June 21, 2022

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL

In final ELIANA analysis, 55% of patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) who were treated with CAR-T cell therapy Kymriah were still alive after five years1 Nearly

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial